Addressing the COVID-19 challenge with computer modeling & simulation
Each day, we wake up hoping for positive news about vaccines and therapies to combat COVID-19. More than 70 candidate molecules are being evaluated for repurposing to treat COVID-19. This number will grow thanks to the use of new combination therapies discovered under an aggressive, disciplined, and quantitative approach to evaluating candidates called model-informed drug development. Read More
Shape-shifting may provide coronavirus with a survival advantage
Conformational changes of the SARS-CoV-2 spike protein -- the target of many vaccines and therapies -- may have features that help the virus hide from the host immune system and survive longer in the environment, according to a study published in Science on July 21. Read More
Replicating RNA COVID-19 vaccine shows robust responses in early testing
A replicating RNA vaccine delivered with a lipid-based nanoparticle emulsion has been shown to produce potent antibodies against SARS-CoV-2 in mice and primates with a single immunization, according to a study published in Science Translational Medicine on July 20. Read More
Transarterial chemoperfusion shows promise in mesothelioma patients
According to research presented during a recent virtual session of the Society of Interventional Radiology, there has been progress on a novel treatment for patients with advanced mesothelioma. Read More
SARS-CoV-2 Nsp1 protein effectively blocks host antiviral defenses
A SARS-CoV-2 protein, Nsp1, may play a critical role in weakening antiviral innate immune defenses, according to a study published in Science on July 17. Researchers identified how the viral protein specifically shuts down host protein production and subsequently blocks host immune functions. Read More
Red blood cells offer potential to deliver vaccines
Scientists have developed a biomimetic vaccine-delivery strategy based on an innate immune function of red blood cells that can deliver vaccine nanoparticles to the spleen, according to a research article published in the Proceedings of the National Academy of Sciences on July 14. Read More
The race is on to create a COVID-19 vaccine. But what next?
Fears of continuing waves of infection with the SARS-CoV-2 virus have helped trigger an accelerated effort among drug developers to bring a coronavirus vaccine to market. But even after a vaccine is developed and approved, there are a host of other challenges that must be solved to make sure it is administered widely enough to protect society at large. Read More
Moderna reports positive results in COVID-19 vaccine trial
Moderna is reporting positive results with a COVID-19 vaccine candidate it is developing. The candidate, messenger RNA (mRNA)-1273, was safe and triggered immune responses in healthy adults, according to new results published July 14 in the New England Journal of Medicine. Read More
Life science instrumentation market adapts to COVID-19
To reflect the new realities of the analytical instrumentation market during the COVID-19 pandemic and in the subsequent pandemic-driven recession, Strategic Directions International, a sister company of ScienceBoard.net, has released its revised edition of the Global Assessment Report. Read More
Could COVID-19 end standoff on tests developed in laboratories?
During the COVID-19 pandemic, research and clinical laboratories were working overtime to develop tests that would help them identify and understand SARS-CoV-2, according to Kalorama Information, a sister company of The Science Advisory Board. These lab-developed tests have become an essential component in the fight against the virus. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
